Redox dysregulation and oxidative stress in schizophrenia: Nutrigenetics as a challenge in psychiatric disease prevention

World Review of Nutrition and Dietetics

Volumn 101, Issue , 2010, Pages 131-153

  Do, Kim Q ^a,b   Conus, Philippe ^a   Cuenod, Michel ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Center for Psychiatric Neuroscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; DIET THERAPY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; NUTRIGENOMICS; NUTRITION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA;

BRAIN; HUMANS; NUTRIGENOMICS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OXIDATION-REDUCTION; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 84926119108     PISSN: 00842230     EISSN: 16623975     Source Type: Book Series    
DOI: 10.1159/000314518     Document Type: Conference Paper

References (185)

1. Insel TR: Disruptive insights in psychiatry: transforming a clinical discipline. J Clin Invest 2009;119: 700-705.
2. Andreasen NC: Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 2000;31:106-112.
3. Lewis DA, Lieberman JA: Catching up on schizophrenia: natural history and neurobiology. Neuron 2000;28:325-334.
4. Cardno AG, Gottesman II: Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet 2000;97:12-17.
5. Barr CL, Kennedy JL, Pakstis AJ, et al: Progress in a genome scan for linkage in schizophrenia in a large Swedish kindred. Am J Med Genet 1994;54:51-58.
6. Coon H, Jensen S, Holik J, et al: Genomic scan for genes predisposing to schizophrenia. Am J Med Genet 1994;54:59-71.
7. Blouin JL, Dombroski BA, Nath SK, et al: Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998;20:70-73.
8. Brzustowicz LM, Honer WG, Chow EW, et al: Linkage of familial schizophrenia to chromosome 13q32. Am J Hum Genet 1999;65:1096-1103.
9. Pulver AE: Search for schizophrenia susceptibility genes. Biol Psychiatry 2000;47:221-230.
10. Mcguffin P, Tandon K, Corsico A: Linkage and association studies of schizophrenia. Curr Psychiatry Rep 2003;5:121-127.
11. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA: Mapping complex disease loci in whole-genome association studies. Nature 2004;429:446-452.
12. Stefansson H, Rujescu D, Cichon S, et al: Large recurrent microdeletions associated with schizophrenia. Nature 2008;455:232-236.
13. Rujescu D, Ingason A, Cichon S, et al: Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009;18:988-996.
14. International Schizophrenia Consortium: Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008;455:237-241.
15. Hoogendoorn ML, Vorstman JA, Jalali GR, et al: Prevalence of 22q11 2 deletions in 311 Dutch patients with schizophrenia. Schizophr Res 2008;98: 84-88.
16. O'Donovan MC, Craddock N, Norton N, et al: Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008;40:1053-1055.
17. Sklar P: Genomewide association for schizophrenia: the Broad/Stanley study. World Congress of Psychiatric Genetics, 2008.
18. Blackwood DH, Fordyce A, Walker MT, et al: Schizophrenia and affective disorders: cosegrega-tion with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001;69: 428-433.
19. Tosato S, Dazzan P, Collier D: Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull 2005;31:613-617.
20. Tosic M, Ott J, Barral S, et al: Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006;79: 586-592.
21. Gysin R, Kraftsik R, Sandell J, et al: Impaired gluta-thione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007;104:16621-16626.
22. Caspi A, Moffitt TE, Cannon M, et al: Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-1127.
23. Nicodemus KK, Straub RE, Egan MF, Weinberger DR: Evidence for statistical epistasis between (COMT) Val158Met polymorphism and multiple putative schizophreia susceptibility genes. Am J Med Genet B Neuropsychiatr Genet 2005;138B:130-131.
24. Leweke FM, Gerth C W, Koethe D, et al: Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004;254:4-8.
25. Cannon TD, Rosso IM, Hollister JM, et al: A prospective cohort study of genetic and perinatal influences in the etiology of schizophrenia. Schizophr Bull 2000;26:351-366.
26. Rosso IM, Cannon TD, Huttunen T, et al: Obstetric risk factors for early-onset schizophrenia in a Finnish birth cohort. Am J Psychiatry 2000;157:801-807.
27. Marcelis M, Van Os J, Sham P, et al: Obstetric complications and familial morbid risk of psychiatric disorders. Am J Med Genet 1998;81:29-36.
28. Petronis A: The origin of schizophrenia: genetic thesis, epigenetic antithesis and resolving synthesis. Biol Psychiatry 2004;55:965-970.
29. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-669.
30. Murray RM, Lewis SW: Is schizophrenia a neurode-velopmental disorder? Br Med J (Clin Res Ed) 1987; 295:681-682.
31. Lewis DA, Levitt P: Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002;25: 409-432.
32. Selemon LD, Goldman-Rakic PS: The reduced neu-ropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999;45:17-25.
33. Parnas J, Bovet P, Innocenti GM: Schizophrenic trait features binding and cortico-cortical connectivity: a neurodevelopmental pathogenetic hypothesis. Neurol Psychiatry Brain Res 1996;4:185-196
34. Friston KJ: The disconnection hypothesis. Schizophrenia Res 1998;30:115-125.
35. Raedler TJ, Knable MB, Weinberger DR: Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol 2000;8:157-161.
36. Matthysse S: Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed Proc 1973;32:200-205.
37. Carlsson A: The current status of the dopamine hypothesis of schizophrenia. Neuropsycho-pharmacology 1988;1:179-186.
38. Lewis DA, Gonzalez-Burgos G: Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006;12:1016-1022.
39. Tamminga CA, Lahti AC, Medoff DR, Gao XM, Holcomb HH: Evaluating glutamatergic transmission in schizophrenia. Ann NY Acad Sci 2003;1003: 113-118.
40. Moghaddam B: Bringing order to the glutamate chaos in schizophrenia. Neuron 2003;40:881-884.
41. Coyle JT: Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26: 365-384.
42. Benes FM, Berretta S: GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25:1-27.
43. Volk DW, Pierri JN, Fritschy JM, et al: Reciprocal alterations in pre-and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002;12:1063-1070.
44. Beasley CL, Zhang ZJ, Patten I, Reynolds GP: Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 2002; 52:708-715.
45. Hashimoto T, Volk D W, Eggan SM, et al: Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003;23:6315-6326.
46. Lewis DA, Hashimoto T, Volk DW: Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005;6:312-324.
47. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT: Neurobiology of schizophrenia. Neuron 2006;52:139-153.
48. Garey LJ, Ong WY, Patel TS, et al: Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 1998;65:446-453.
49. Glantz LA, Lewis DA: Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000;57:65-73.
50. Rosoklija G, Toomayan G, Ellis S P, et al: Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 2000;57:349-356.
51. Kolluri N, Sun Z, Sampson AR, Lewis DA: Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2005;162:1200-1202.
52. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA: Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000;57: 237-245.
53. Lim KO, Helpern JA: Neuropsychiatric applications of DTI-a review. NMR Biomed 2002;15:587-593.
54. Kanaan RA, Kim JS, Kaufmann WE, et al: Diffusion tensor imaging in schizophrenia. Biol Psychiatry 2005;58:921-929.
55. Engel AK, Konig P, Kreiter AK, Singer W: Interhemispheric synchronization of oscillatory neuronal responses in cat visual cortex. Science 1991;252:1177-1179.
56. Singer W, Gray CM: Visual feature integration and the temporal correlation hypothesis. Annu Rev Neurosci 1995;18:555-586.
57. Tallon-Baudry C, Bertrand O: Oscillatory gamma activity in humans and its role in object representation. Trends Cogn Sci 1999;3:151-162.
58. Spencer KM, Nestor PG, Niznikiewicz MA, et al: Abnormal neural synchrony in schizophrenia. J Neurosci 2003;23:7407-7411.
59. Uhlhaas PJ, Singer W: Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 2006;52:155-168.
60. Jalili M, Lavoie S, Deppen P, et al: Dysconnection topography in schizophrenia revealed with state-space analysis of EEG. PLoS ONE 2007;2:e1059.
61. Knyazeva MG, Jalili M, Meuli R, et al: Alpha rhythm and hypofrontality in schizophrenia. Acta Psychiatr Scand 2008;118:188-199.
62. Shelley AM, Ward PB, Catts S V, et al: Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 1991;30: 1059-1062.
63. Umbricht D, Javitt D, Novak G, et al: Effects of clo-zapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998;44:716-725.
64. Umbricht D, Schmid L, Koller R, et al: Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000;57:1139-1147.
65. Insel TR: Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009;66:128-133.
66. Lu SC: Regulation of glutathione synthesis. Mol Aspects Med 2008;30:42-59.
67. Jones DP: Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008;295:C849-C868.
68. Shi ZZ, Osei-Frimpong J, Kala G, et al: Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc Natl Acad Sci USA 2000;97:5101-5106.
69. Lipton SA, Choi YB, Takahashi H, et al: Cysteine regulation of protein function as exemplified by NMDA-receptor modulation. Trends Neurosci 2002;25:474-480.
70. Valko M, Leibfritz D, Moncol J, et al: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39: 44-84.
71. Mahadik SP, Mukherjee S: Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Res 1996;19:1-17.
72. Yao JK, Reddy RD, van Kammen DP: Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001;15:287-310.
73. Herken H, Uz E, Ozyurt H, et al: Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66-73.
74. Ben-Shachar D: Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem2002;83:1241-1251.
75. Zhang XY, Tan YL, Cao LY, et al: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Res 2006;81:291-300.
76. Prabakaran S, Swatton JE, Ryan MM, et al: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxi-dative stress. Mol Psychiatry 2004;9:684-697.
77. Evans DR, Parikh V V, Khan MM, et al: Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003;69:393-399.
78. Marchbanks RM, Ryan M, Day IN, et al: A mito-chondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophrenia Res 2003;65:33-38.
79. Do KQ, Bovet P, Cabungcal JH, et al: Redox dysreg-ulation in schizophrenia: genetic susceptibility and pathophysiological mechanisms; in Lajtha A: Handbook of Neurochemistry and Molecular Neurobiology. New York, Springer, vol 27, 2009.
80. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al: Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000;12:3721-3728.
81. Yao JK, Leonard S, Reddy R: Altered glutathione redox state in schizophrenia. Dis Markers 2006;22: 83-93.
82. 1H-MRS study. PLoS ONE 2008;3:e1944.
83. Raffa M, Mechri A, Othman LB, et al: Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1178-1183.
84. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M: Redox dysregulation neurodevelopment and schizophrenia. Curr Opin Neurobiol 2009;19:220-230.
85. Cabungcal JH, Nicolas D, Kraftsik R, et al: Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis 2006;22:624-637.
86. Grima G, Benz B, Parpura V, Cuenod M, Do KQ: Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 2003;62:213-224.
87. Steullet P, Neijt HC, Cuenod M, Do KQ: Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006;137:807-819.
88. Steullet P, Lavoie S, Kraftsik R, et al: A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons. Free Radic Biol Med 2008;44:1042-1054.
89. Castagne V, Rougemont M, Cuenod M, Do KQ: Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 2004;15: 93-105.
90. Castagne V V, Cuenod M, Do KQ: An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder: Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience 2004;123:821-834.
91. Cabungcal JH, Preissmann D, Delseth C, et al: Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. Neurobiol Dis 2007;26:634-645.
92. Piazza PV, Le Moal ML: Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress glucocorticoids and dopaminergic neurons. Annu Rev Pharmacol Toxicol 1996;36:359-378.
93. Barrot M, Abrous DN, Marinelli M, et al: Influence of glucocorticoids on dopaminergic transmission in the rat dorsolateral striatum. Eur J Neurosci 2001; 13:812-818.
94. Ganguli R, Singh A, Brar J, Carter C, Mintun M: Hydrocortisone induced regional cerebral activity changes in schizophrenia: a PET scan study. Schizophrenia Res 2002;56:241-247.
95. Liu J Wang X, Shigenaga MK, Yeo HC, Mori A, Ames BN: Immobilization stress causes oxidative damage to lipid protein and DNA in the brain of rats. FASEB J 1996;10:1532-1538.
96. Harrison PJ: The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999;122:593-624.
97. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH: NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 1994;12: 1031-1040.
98. Krystal JH, Karper L P, Seibyl J P, et al: Subanesthetic effects of the noncompetitive NMDA antagonist ketamine in humans: psychotomimetic perceptual cognitive and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
99. Kempf L, Nicodemus KK, Kolachana B, et al: Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and frontostriatal structure and function. PLoS Genet 2008;4:e1000252.
100. Phang JM, Donald SP, Pandhare J, Liu Y: The metabolism of proline a stress substrate modulates carcinogenic pathways. Amino Acids 2008;35:681-690.
101. Fuchs EC, Zivkovic AR, Cunningham MO, et al: Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron 2007;53:591-604.
102. Davis KL, Haroutunian V: Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362:758.
103. Abekawa T, Ito K, Nakagawa S, Koyama T: Prenatal exposure to an NMDA receptor antagonist MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperloco-motion but not behavioral sensitization to metham-phetamine in postpubertal rats. Psychopharmacology (Berl) 2007;192:303-316.
104. Rujescu D, Bender A, Keck M, et al: A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular cellular functional and behavioral abnormalities. Biol Psychiatry 2006;59:721-729.
105. Wang CZ, Yang SF, Xia Y, Johnson KM: Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneu-rons. Neuropsychopharmacology 2008;33:2442-2455.
106. Behrens MM, Ali SS, Dao DN, et al: Ketamine-induced loss of phenotype of fast-spiking interneu-rons is mediated by NADPH-oxidase. Science 2007; 318:1645-1647.
107. Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
108. Uhlhaas PJ, Linden DE, Singer W, et al: Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J Neurosci 2006;26:8168-8175.
109. Li Z, Dong T, Proschel C, Noble M: Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol2007;5:e35
110. Smith J, Ladi E, Mayer-Proschel M, Noble M: Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell: Proc Natl Acad Sci USA 2000; 97:10032-10037.
111. Robertson GS, Hori SE, Powell KJ: Schizophrenia: an integrative approach to modelling a complex disorder. J Psychiatry Neurosci 2006;31:157-167.
112. O'tuathaigh CM, Babovic D, O'meara G, et al: Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of pheno-typic behaviour. Neurosci Biobehav Rev 2007;31: 60-78.
113. Rougemont M, Do KQ, Castagne V: A new model of glutathione deficit during development: effect of glutathione deficit on lipid peroxidation in the rat brain. J Neurosci Res 2003;70:774-783.
114. Steullet P, Cabungcal JH, Kulak A, et al: Redox dys-regulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations and related behaviours. J Neurosci 2010;30:2547-2558.
115. Do KQ, Conus P, Bovet P, et al: developmental critical period in genetic redox dysregulation: animal and human studies in schizophrenia. Schizophr Bull 2009;35:106-107.
116. Behrens MM, Ali SS, Dao DN, et al: Ketamine-induced loss of phenotype of fast-spiking interneu-rons is mediated by NADPH-oxidase. Science 2007;318:1645-1647.
117. Uhlhaas PJ, Haenschel C, Nikolic D, Singer W: The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull 2008;34:927-943.
118. Kubicki M, McCarley R, Westin CF, et al: A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res 2007;41:15-30.
119. Kyriakopoulos M, Vyas NS, Barker GJ, Chitnis XA, Frangou S: A diffusion tensor imaging study of white matter in early-onset schizophrenia. Biol Psychiatry 2008;63:519-523.
120. Zafarullah M, Li WQ, Sylvester J, Ahmad M: Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003;60:6-20.
121. Tirouvanziam R, Conrad CK, Bottiglieri T, et al: High-dose oral N-acetylcysteine a glutathione prod-rug modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006;103:4628-4633.
122. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552-1560.
123. Arakawa M, Ito Y: N-acetylcysteine and neurode-generative diseases: basic and clinical pharmacology. Cerebellum 2007;1-7.
124. Adair JC, Knoefel JE, Morgan N: Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001;57:1515-1517.
125. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI: N-acetyl-l-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Clin Neurosci 2000;11:2491-2493.
126. Zhou W, Kalivas PW: N-acetylcysteine reduces extinction responding and induces enduring reductions in cue-and heroin-induced drug-seeking. Biol Psychiatry 2008;63:338-340.
127. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA: N-Acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7:355-359.
128. Cotgreave IA: N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997;38:205-227.
129. Berk M, Copolov D, Dean O, et al: N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:361-368.
130. Lavoie S, Murray MM, Deppen P, et al: Glutathione precursor N-acetyl-cysteine improves mismatch negativity in schizophrenia patients. Neuropsycho pharmacology 2008;33:2187-2199.
131. Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG Jr: Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry 1993;33:513-519.
132. Berk M, Copolov DL, Dean O, et al: N-acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468-475.
133. Crow TJ: The continuum of psychosis and its implication for the structure of the gene. Br J Psychiatry 1986;149:419-429.
134. McGorry PD, Yung AR: Early intervention in psychosis: an overdue reform. Aust NZ J Psychiatry 2003;37:393-398.
135. Killackey E, Yung AR, McGorry PD: Early psychosis: where we've been, where we still have to go. Epidemiol Psichiatr Soc 2007;16:102-108.
136. Falloon IR: Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992;55:4-15.
137. Loebel AD, Lieberman JA, Alvir JM, et al: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-1188.
138. McGlashan TH: Early detection and intervention in schizophrenia: research. Schizophr Bull1996;22:327-345.
139. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ: EPPIC: an evolving system of early detection and optimal management. Schizophr Bull1996;22:305-326
140. Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996;22:353-370.
141. Yung AR, Nelson B, Stanford C, et al: Validation of 'prodromal' criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 2008;105:10-17.
142. McGorry PD, Yung AR, Bechdolf A, Amminger P: Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry 2008;65:25-27.
143. Cannon TD, Cadenhead K, Cornblatt B, et al: Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37.
144. Birchwood M, Todd P, Jackson C: Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry Suppl 1998;172(suppl 33):53-59.
145. Conus P, Montagrin Y, Bircher R, et al: TIPP-Lausanne first episode psychosis program: patients' baseline characteristics and impact of the program on adherence to psychosocial treatment. Schizophr Res 2008;98(suppl 1):81.
146. McGlashan TH, Miller TJ, Woods SW: Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull 2001;27:563-570.
147. Phillips LJ, McGorry PD, Yung AR, et al: Prepsychotic phase of schizophrenia and related disorders: recent progress and future opportunities. Br J Psychiatry Suppl 2005;48:s33-s44.
148. 12 homocysteine and the MTHFR 677C→T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003;60:618-626.
149. James SJ, Cutler P, Melnyk S, et al: Metabolic bio-markers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80:1611-1617.
150. Smythies JR, Gottfries CG, Regland B: Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Biol Psychiatry 1997;41:230-233.
151. Muskiet FA, Kemperman RF: Folate and long-chain polyunsaturated fatty acids in psychiatric disease. J Nutr Biochem 2006;17:717-727.
152. Regland B, Johansson B V, Gottfries CG: Homo-cysteinemia and schizophrenia as a case of methyla-tion deficiency. J Neural Transm Gen Sect 1994;98:143-152.
153. Regland B: Schizophrenia and single-carbon metabolism. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1124-1132.
154. Park LC, Baldessarini RJ, Kety SS: Methionine effects on chronic schizophrenics. Arch Genet Psychiatry 1965;12:346-351.
155. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M: How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29:190-201.
156. Connor H, Newton DJ, Preston FE, Woods HF: Oral methionine loading as a cause of acute serum folate deficiency: its relevance to parenteral nutrition. Postgrad Med J 1978;54:318-320.
157. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G: Peroxidation indices and total antioxidant capacity in plasma during hyperhomocysteinemia induced by methionine oral loading. Metabolism 2000;49:225-228.
158. Raijmakers MT, Schilders G W, Roes EM, et al: N-acetylcysteine improves the disturbed thiol redox balance after methionine loading. Clin Sci (Lond) 2003;105:173-180.
159. Avila MA, Corrales FJ, Ruiz F, et al: Specific interaction of methionine adenosyltransferase with free radicals. Biofactors 1998;8:27-32.
160. Gomes-Trolin C, Yassin M, Gottfries CG, et al: Erythrocyte and brain methionine adenosyltrans-ferase activities in patients with schizophrenia. J Neural Transm 1998;105:1293-1305.
161. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M: How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29:190-201.
162. Abdolmaleky HM, Smith CL, Faraone S V, et al: Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet 2004;127B:51-59.
163. Abdolmaleky HM, Cheng KH, Russo A, et al: Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005;134:60-66.
164. Godfrey PS, Toone BK, Carney M W, et al: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-395.
165. Yehuda S, Rabinovitz S, Mostofsky DI: Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 1999;56:565-570.
166. Simopoulos AP: Importance of the ratio of omega-6/omega-3 essential fatty acids: evolutionary aspects. World Rev Nutr Diet 2003;92:1-22.
167. Keshavan MS, Mallinger AG, Pettegrew J W, Dippold C: Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res 1993;49:89-95.
168. Reddy RD, Keshavan MS, Yao JK: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 2004;30:901-911.
169. Mahadik S P, Mukherjee S, Correnti EE, et al: Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res 1994;13:239-247
170. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M: Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991;30:795-805.
171. Pettegrew J W, Keshavan MS, Panchalingam K, et al: Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode drug-naive schizophrenics: a pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991;48:563-568.
172. Yao J, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW: Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry 2002;52:823-830.
173. Altar CA, Jurata LW, Charles V, et al: Deficient hip-pocampal neuron expression of proteasome ubiq-uitin and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 2005;58:85-96.
174. Freeman M P, Hibbeln JR, Wisner KL, et al: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006; 67:1954-1967.
175. Peet M, Horrobin DF: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36:7-18.
176. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-919.
177. Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-479.
178. Su KP, Huang SY, Chiu CC, Shen WW: Omega-3 fatty acids in major depressive disorder: a preliminary double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-271.
179. Ross BM, Seguin J, Sieswerda LE: Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007;6: 21.
180. Bentsen H, Lingjaerde O, Solberg DK, Murck H: A multicentre placebo-controlled trial of eicosapen-taenoic acid and antioxidant supplementation in the treatment of schizophrenia and related disorders. Schizophr Res 2006;81:29.
181. Gerster H: High-dose vitamin C: a risk for persons with high iron stores? Int J Vitam Nutr Res 1999; 69:67-82.
182. Podmore ID, Griffiths HR, Herbert KE, et al: Vitamin C exhibits pro-oxidant properties. Nature 1998;392:559.
183. Smythies JR, Gottfries CG, Regland B: Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Biol Psychiatry 1997;41:230-233.
184. Handy DE, Zhang Y, Loscalzo J: Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 2005; 280:15518-15525.
185. Vitvitsky V, Prudova A, Stabler S, et al: Testosterone regulation of renal cystathionine beta-synthase: implications for sex-dependent differences in plasma homocysteine levels. Am J Physiol Renal Physiol 2007;293:F594-F600